What insurance policy changes affect HCPCS J3389?

There are 22 tracked policy changes affecting HCPCS J3389, including updates from Anthem BCBS, Harvard Pilgrim Health Care, Texas Medicaid. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for HCPCS J3389?

Payers that have issued tracked updates for HCPCS J3389 include: Anthem BCBS, Harvard Pilgrim Health Care, Texas Medicaid, Blue Cross Blue Shield of North Dakota, Humana, Blue Cross & Blue Shield of Mississippi.

How do I get notified when HCPCS J3389 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to HCPCS J3389. You will receive a daily digest email whenever a new policy change references this code.

Why do payers change policies for HCPCS J3389?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

J3389 — Topical administration, prademagene zamikeracel, per treatment: Insurance Policy Changes

J3389 Insurance Policy Changes

HCPCS J3389 is officially defined as "Topical administration, prademagene zamikeracel, per treatment." HCPCS J3389 is referenced in 22 tracked payer policy changes from Anthem BCBS, Harvard Pilgrim Health Care, and 4 other payers. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for HCPCS J3389 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Medium impact

[Ohio] Precertification/prior authorization list change notification

Anthem BCBS·Effective Dec 1, 2026

Anthem Blue Cross and Blue Shield (Ohio) is adding 14 new services to its precertification/prior authorization requirements effective December 1, 2026. These additions include four specialized laboratory tests (Alzheimer's biomarkers, IBS serology, infectious disease sequencing, prostate cancer protein biomarkers), two irreversible electroporation procedures, six carotid sinus baroreceptor stimulation device codes, and two gene therapy treatments. All affected services will require prior authorization before billing to avoid claim denials.

J3389 Insurance Policy Changes

[Ohio] Precertification/prior authorization requirement changes

[California] Precertification/prior authorization requirement changes

[Virginia] Prior authorization requirement changes

[Virginia] Precertification/prior authorization requirement changes

[Georgia] Precertification/prior authorization list change notification

[California] Prior authorization requirement changes

[California] Prior authorization requirement changes

[New York] Prior authorization requirement changes

[New York] Precertification/prior authorization requirement changes

[Ohio] Precertification/prior authorization requirement changes

[Virginia] Prior authorization requirement changes

[Georgia] Precertification/prior authorization requirement changes

[New York] Precertification/prior authorization list change notification

[Virginia] Precertification/prior authorization list change notification

[Ohio] Precertification/prior authorization list change notification

Point32Health medical drug program updates

First Quarter 2026 HCPCS Updates for Texas Medicaid

Pharmacy Policy Updates

Zevaskyn (prademagene zamikeracel) - Medicare Advantage (Revised)

Prior Authorization Criteria for Prademagene Zamikeracel (Zevaskyn) Effective May 1, 2026

Zevaskyn (prademagene zamikeracel)

State and School Employees' Health Insurance Plan - Zevaskyn (prademagene zamikeracel)